Core Points - The resignation of Ms. Tan Haiyan as the securities affairs representative of Sailong Pharmaceutical Group Co., Ltd. has been announced due to personal career development reasons [1] - Ms. Tan will no longer hold any positions within the company or its subsidiaries after her resignation takes effect [1] - The company expresses gratitude for Ms. Tan's contributions during her tenure and assures that her resignation will not affect the normal operations of the company [1] - The company will promptly appoint a qualified individual to take over the role of securities affairs representative in accordance with relevant regulations [1]

Company Overview - *ST Sailong (SZ 002898) announced the resignation of Ms. Tan Haiyan as the securities affairs representative due to personal career development reasons. After her resignation, she will no longer hold any positions in the company or its subsidiaries [1] Financial Performance - For the first half of 2025, *ST Sailong's revenue composition is as follows: pharmaceutical manufacturing accounts for 59.82%, the electronics industry accounts for 39.78%, and other businesses account for 0.4% [1] - As of the report date, *ST Sailong has a market capitalization of 2.4 billion yuan [1]

Core Viewpoint - The resignation of the securities affairs representative, Tan Haiyan, is due to personal career development plans, and it will not affect the normal operations of the company [1] Group 1 - The board of directors received a written resignation report from Tan Haiyan, which is effective immediately upon delivery to the board [1] - After the resignation, Tan Haiyan will no longer hold any position in the company or its subsidiaries [1] - As of the announcement date, Tan Haiyan did not hold any shares and had no unfulfilled commitments [1] Group 2 - The company will promptly appoint a new securities affairs representative in accordance with regulations [1]

证券代码：002898 证券简称：*ST赛隆 公告编号：2025-091 赛隆药业集团股份有限公司 关于证券事务代表辞职的公告 特此公告。 赛隆药业集团股份有限公司 董事会 2025年11月18日 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没 有虚假记载、误导性陈述或重大遗漏。 赛隆药业集团股份有限公司（以下简称"公司"）董事会于近日收到公司 证券事务代表谭海雁女士的书面辞职报告，谭海雁女士因个人职业发展规划原 因申请辞去公司证券事务代表一职，辞职申请自送达董事会之日起生效。辞职 后，谭海雁女士将不再担任公司及子公司的任何职务。 截至本公告披露日，谭海雁女士未持有公司股份，不存在应当履行而未履 行的承诺事项。谭海雁女士在任职期间恪尽职守、勤勉尽责，公司及公司董事 会对谭海雁女士在任职期间为公司所做的贡献表示衷心感谢！ 谭海雁女士的辞职不会影响公司相关工作的正常开展，公司将根据《深圳 证券交易所股票上市规则》、《深圳证券交易所上市公司自律监管指引第 1 号—主板上市公司规范运作》等相关规定，尽快聘任符合任职资格的相关人士 担任证券事务代表，协助董事会秘书开展工作。 ...

Core Viewpoint - *ST Sailong (002898.SZ) has recently received approval from the National Medical Products Administration for the injection of Nicorandil, which is indicated for the treatment of unstable angina pectoris [1] Company Summary - The wholly-owned subsidiary of *ST Sailong, Hunan Sailong Pharmaceutical (Changsha) Co., Ltd., has obtained the drug registration certificate for injectable Nicorandil [1]

Group 1 - The core point of the article is that *ST Sailong has received approval from the National Medical Products Administration for its injectable Nicorandil product, which is a significant development for the company [1] - As of January to June 2025, *ST Sailong's revenue composition is as follows: 59.82% from the pharmaceutical manufacturing sector, 39.78% from the electronics sector, and 0.4% from other businesses [1] - The current market capitalization of *ST Sailong is 2.3 billion yuan [1]

证券代码：002898 证券简称：*ST 赛隆 公告编号：2025-090 赛隆药业集团股份有限公司 剂型：注射剂 规格：12mg、48mg 注册分类：化学药品 3 类 证书编号：2025S03328/2025S03329 关于子公司获得注射用尼可地尔药品注册证书 的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 赛隆药业集团股份有限公司（以下简称"公司"）全资子公司湖南赛隆药业 （长沙）有限公司于近日获得国家药品监督管理局核准签发的注射用尼可地尔 《药品注册证书》，现将相关情况公告如下： 一、药品基本信息 药品名称：注射用尼可地尔 董事会 2025 年 11 月 15 日 药品注册标准编号：YBH25562025 药品批准文号：国药准字 H20255868、国药准字 H20255869 药品批准文号有效期：至 2030 年 11 月 03 日 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，本品 符合药品注册的有关要求，批准注册，发给药品注册证书。质量标准、说明书、 标签及生产工艺照所附执行。药品生产企业应当符合药品生产质量管理规范要求 ...

Core Viewpoint - *ST Sailong (002898) announced that its wholly-owned subsidiary, Hunan Sailong Pharmaceutical (Changsha) Co., Ltd., has recently received the drug registration certificate for injectable Nicorandil from the National Medical Products Administration, which is used for the treatment of unstable angina pectoris [1] Group 1 - The approval of injectable Nicorandil represents a significant milestone for the company in expanding its product portfolio [1] - Injectable Nicorandil is specifically indicated for the treatment of unstable angina pectoris, addressing a critical medical need in the cardiovascular sector [1]

Core Viewpoint - The company has received approval for the injectable Nicorandil from the National Medical Products Administration, which is intended for the treatment of unstable angina pectoris, enhancing its product portfolio [1] Group 1: Product Approval - The company's wholly-owned subsidiary, Hunan Sailong Pharmaceutical (Changsha) Co., Ltd., has recently obtained the drug registration certificate for injectable Nicorandil [1] - The approval of injectable Nicorandil will further enrich the company's formulation varieties [1] Group 2: Market Considerations - The sales performance of the newly approved drug will depend on various internal and external environmental changes, indicating a level of uncertainty [1] - The company commits to timely information disclosure based on subsequent developments [1]

Core Viewpoint - The announcement details the pledge of shares by a major shareholder, Cai Nanguai, which exceeds 80% of his holdings, raising potential concerns for investors regarding the company's financial stability and governance [1][8]. Shareholder Pledge Basic Situation - Cai Nanguai holds 67,512,703 shares, making him the largest shareholder but not the controlling shareholder. He has signed a commitment to waive voting rights on his remaining shares [1]. - The pledged shares do not involve any major asset restructuring or performance compensation obligations [1]. Cumulative Pledge Situation - As of the announcement date, the pledged shares include those of Cai Nanguai and his concerted actions, with specific details on the number of shares pledged and their status [2]. Financing and Use of Pledged Shares - Part of the financing from the pledged shares will be used to provide loans to the company to support its operations, while the remainder is for personal funding needs [3][6]. - Cai Nanguai and his concerted actions have no upcoming pledge financing due within the next six months or one year, indicating a stable financial situation [3]. Risk Management and Control - Cai Nanguai's high proportion of pledged shares is primarily to support company development and personal funding needs. He has a good credit status and repayment capability, with no debt repayment risk [7]. - The company’s control has changed, but this will not affect its operations or governance [5][8]. Guarantees and Loans - Cai Nanguai has provided guarantees for credit limits totaling 60 million yuan to banks, with no counter-guarantees from the company or its subsidiaries, incurring no related costs [7]. - He has also provided loans to the company up to 160 million yuan at an annual interest rate of 3.0%, calculated based on actual borrowing amounts and days used [7].